Rapport Therapeutics, Inc.
RAPPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering. At a $1.24B market cap, Rapport Therapeutics, Inc. ranks as a small-cap company within healthcare. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Market Cap
$1.24B
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-5.10
EPS (TTM)
$-3.03
EPS (Fwd)
$-5.09
ROE
-40.0%
ROA
-25.8%
Cash
$436.1M
Total Debt
$10.1M
Free CF
-$56.0M
52W Change
-2.1%
Annual Financials
Cash vs Debt
Where RAPP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RAPP finished 25.31% below its 150-day moving average ($38.29) and 20.00% below its 200-day moving average ($35.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RAPP overbought or oversold?
At the October 20, 2026 close, RAPP's RSI(14) was 31.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $436.1M in cash comfortably exceeding the $10.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$56.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -40.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, RAPP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RAPP.